Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Chief Scientific Officer | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Syndax Pharmaceuticals Inc
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-02-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-02-15 · Exercise / conversion · Acquired 7,572 · Balance 7,572 Row 2 · 2023-02-15 · Sale · Disposed 7,572 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested. F2: The sale prices ranged from $25.53 to $26.10. Row 3 · 2023-02-15 · Exercise / conversion · Acquired 17,428 · Balance 17,428 Row 4 · 2023-02-15 · Sale · Disposed 17,428 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested. F2: The sale prices ranged from $25.53 to $26.10. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.20 · Expires 2025-06-01 | Direct | 0 |
Reported balance
After 2023-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-02-15 · Exercise / conversion · Disposed 17,428 · Balance 0 F3: This option is fully vested. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2023-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-02-15 · Exercise / conversion · Disposed 7,572 · Balance 0 F3: This option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested.
F2: The sale prices ranged from $25.53 to $26.10.
F3: This option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 17, 2023 23:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 7,572 | $25.84 Strike: $6.38 | $195,688.50 |
DisclosureSEC source: 0001562180-23-001533 · primarydocument.xml · derivative · entry 6 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,572 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 17,428 | $25.84 Strike: $7.20 | $450,404.00 |
DisclosureSEC source: 0001562180-23-001533 · primarydocument.xml · derivative · entry 5 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,428 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 17,428 | $25.84 | $450,404.00 |
DisclosureSEC source: 0001562180-23-001533 · primarydocument.xml · nonDerivative · entry 4 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.53 to $26.10. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 17,428 | $7.20 | $125,481.60 |
DisclosureSEC source: 0001562180-23-001533 · primarydocument.xml · nonDerivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 7,572 | $25.84 | $195,688.50 |
DisclosureSEC source: 0001562180-23-001533 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.53 to $26.10. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:09 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 7,572 | $6.38 | $48,309.36 |
DisclosureSEC source: 0001562180-23-001533 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 21:59 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 90,000 | $28.55 Strike: $28.55 | $2,569,500.00 |
DisclosureSEC source: 0001562180-23-000950 · primarydocument.xml · derivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:59 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 69 | $28.43 | $1,961.54 |
DisclosureSEC source: 0001562180-23-000950 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 21:59 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 69 | $17.32 | $1,195.08 |
DisclosureSEC source: 0001562180-23-000950 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 69 shares by the Reporting Person on 01/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 17,200 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · derivative · entry 9 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,200 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 17,200 | $25.05 | $430,935.68 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · nonDerivative · entry 6 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $25.00 to $25.19. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 17,200 | $6.38 | $109,736.00 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · nonDerivative · entry 5 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 3,772 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · derivative · entry 8 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,772 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 4,028 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · derivative · entry 7 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,028 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 4,028 | $25.01 | $100,745.92 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · nonDerivative · entry 4 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.00 to $25.03. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 4,028 | $6.38 | $25,698.64 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · nonDerivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 3,772 | $25.01 | $94,343.00 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.00 to $25.03. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 3,772 | $6.35 | $23,952.20 |
DisclosureSEC source: 0001562180-22-008017 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:14 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 22,846 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001562180-22-006334 · primarydocument.xml · derivative · entry 7 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,846 shares Expires 2024-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:14 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,154 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001562180-22-006334 · primarydocument.xml · derivative · entry 6 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,154 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:14 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 2,154 | $25.04 | $53,926.90 |
DisclosureSEC source: 0001562180-22-006334 · primarydocument.xml · nonDerivative · entry 5 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,647 options to purchase shares of common stock that are vested and immediately exercisable and a total of 148,194 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $25.00 to $25.18. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:14 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 2,154 | $6.35 | $13,677.90 |
DisclosureSEC source: 0001562180-22-006334 · primarydocument.xml · nonDerivative · entry 4 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:14 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 22,846 | $25.04 | $571,965.60 |
DisclosureSEC source: 0001562180-22-006334 · primarydocument.xml · nonDerivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,647 options to purchase shares of common stock that are vested and immediately exercisable and a total of 148,194 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $25.00 to $25.18. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:14 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 22,846 | $6.32 | $144,386.72 |
DisclosureSEC source: 0001562180-22-006334 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2022 Filed Aug 26, 2022 20:14 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 265 | $14.12 | $3,741.80 |
DisclosureSEC source: 0001562180-22-006334 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 265 shares by the Reporting Person on 07/29/2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 80,000 | $15.79 Strike: $15.79 | $1,263,200.00 |
DisclosureSEC source: 0001562180-22-001079 · primarydocument.xml · derivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 1,412 | $16.65 | $23,509.80 |
DisclosureSEC source: 0001562180-22-001079 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 22:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,412 | $12.39 | $17,494.68 |
DisclosureSEC source: 0001562180-22-001079 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,412 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:22 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0001562180-21-000934 · primarydocument.xml · derivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,684 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · derivative · entry 7 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,684 shares Expires 2023-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,288 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · derivative · entry 6 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,288 shares Expires 2023-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 16,334 | $22.89 | $373,924.46 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 5 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The sales prices ranged from $22.34 to $23.32. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 7,954 | $23.58 | $187,594.29 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 4 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,334 F2 · price: The sales prices ranged from $23.35 to $23.94. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 5,684 | $23.33 | $132,602.60 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,288 F1 · price: The sales prices ranged from $22.94 to $23.73. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 5,684 | $3.08 | $17,506.72 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 24,288 | $3.08 | $74,807.04 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:36 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001234 · primarydocument.xml · derivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:28 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-19-000856 · primarydocument.xml · derivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 40,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 40,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| April 03, 2018 Filed Apr 3, 2018 20:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001562180-18-001800 · primarydocument.xml · derivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2023-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 03, 2018 Filed Apr 3, 2018 20:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 7,500 | $15.00 | $112,500.00 |
DisclosureSEC source: 0001562180-18-001800 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Read SEC document |
| April 03, 2018 Filed Apr 3, 2018 20:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 7,500 | $3.08 | $23,100.00 |
DisclosureSEC source: 0001562180-18-001800 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-18-001428 · primarydocument.xml · derivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018. Read SEC document |
| May 17, 2017 Filed May 19, 2017 15:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 732 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001562180-17-002011 · primarydocument.xml · derivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 732 shares Expires 2023-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 17, 2017 Filed May 19, 2017 15:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 5,000 | $15.00 | $75,000.00 |
DisclosureSEC source: 0001562180-17-002011 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Read SEC document |
| May 17, 2017 Filed May 19, 2017 15:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 732 | $3.08 | $2,254.56 |
DisclosureSEC source: 0001562180-17-002011 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 19:13 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-17-000570 · primarydocument.xml · derivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-02-06 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 6, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.